Loading…
Employees: 6,200
Size EBOS (EBO.AX) is an Australia Health Care company (Medical Specialties) with a market value of $2.52B, the 110th largest of 316 Australia companies the cockpit tracks. Shares closed at A$17.29 on 6 Nov 2026.
Performance Over six months the shares gained 1.3%, against -2.6% for the median peer and +4.1% for the Australia market (cap-weighted) — 10th highest of 21 in its peer set.
Growth Revenue grew 3.1% over the last twelve months (peer median +8.4%); the operating margin is 2.8% (peer median 12.2%).
Valuation It trades at 15.2× forward earnings against a peer median of 31.5× (5th cheapest of 19).
Price implies For today's price to make sense, revenue must grow about 4% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is -3 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 0.6 points below its cost of capital (6.4% WACC).
Next results Next results expected around 23 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|---|
| Revenue | A$12.8B | A$12.8B | A$12.5B | A$13.0B | A$12.3B |
| Revenue growth | — | +3% | -4% | +6% | — |
| Gross profit | A$911M | A$909M | A$935M | A$945M | A$921M |
| EBITDA | A$532M | A$530M | A$550M | A$605M | A$574M |
| Net income | A$214M | A$214M | A$218M | A$268M | A$255M |
| Free cash flow | A$214M | A$207M | A$298M | A$249M | A$299M |
| Capital expenditure | A$144M | A$139M | A$148M | A$117M | A$99.0M |
| Total debt | n/a | A$1.89B | A$1.62B | A$1.65B | A$1.28B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | EBO.AX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +13.6% | +5.6% | 5th highest of 21 |
| 6-month return | +1.3% | -2.6% | 10th highest of 21 |
| Distance from 52-week high | -33.5% | -32.7% | 11th highest of 21 |
| Revenue growth (TTM) | +3.1% | +8.4% | 7th lowest of 20 |
| Operating margin | 2.8% | 12.2% | 6th lowest of 20 |
| Forward P/E | 15.2× | 31.5× | 5th cheapest of 19 |
| Growth the price implies (Req g, 7 yrs) | 4.3% | 13.3% | 3rd least demanding of 14 |
| Growth delivered (Del g) | +6.8% | +14.1% | 4th lowest of 14 |
| Hurdle (Req g minus delivered) | -2.5 pp | -2.1 pp | 7th least demanding of 14 |
| ROIC minus cost of capital | -0.6 pp | -0.6 pp | 10th highest of 20 |
| Net debt / EBITDA | 3.1× | -0.2× | 4th most indebted of 13 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| EBOS EBO.AX | Australia | $2.52B | +1% | +3% | 3% | 15.2× | 4.3% | +6.8% |
| Double Medical Technology 002901.SZ | China | $2.56B | -3% | +13% | 26% | 25.9× | 8.3% | +10.4% |
| Neogen NEOG | United States | $2.57B | +30% | 0% | 0% | 34.6× | n/a | n/a |
| Micro-Tech (Nanjing) 688029.SS | China | $2.46B | +3% | +6% | 18% | 29.0× | 12.8% | +19.2% |
| Jafron Biomedical 300529.SZ | China | $2.46B | +8% | +1% | 37% | 25.4× | 6.9% | +0.6% |
| Medacta MOVE.SW | Switzerland | $2.61B | -21% | +8% | 15% | 24.3× | n/a | n/a |
| Elekta EKTA-B.ST | Sweden | $2.37B | +8% | -7% | 6% | 15.1× | 10.0% | +4.0% |
| Shanghai Conant Optical 2276.HK | Hong Kong | $2.27B | -27% | +8% | 29% | 22.1× | -1.6% | +14.1% |
| Metall Zug METN.SW | Switzerland | $2.25B | +19% | 0% | -10% | 139.2× | n/a | n/a |
| COMET COTN.SW | Switzerland | $2.84B | -9% | -3% | 6% | 34.0× | n/a | n/a |
| Bonesupport BONEX.ST | Sweden | $2.16B | +34% | +25% | 25% | 61.9× | 13.3% | +45.4% |
| iRhythm IRTC | United States | $2.97B | -25% | +26% | 1% | 182.6× | n/a | n/a |
| AtriCure ATRC | United States | $2.98B | +123% | +14% | 3% | 220.7× | 55.7% | +20.9% |
| Axogen AXGN | United States | $2.99B | +19% | +24% | -5% | 76.5× | 48.8% | +14.9% |
| TransMedics TMDX | United States | $3.06B | +30% | +26% | 12% | 48.5× | 35.6% | +88.2% |
| Establishment Labs ESTA | United States | $2.00B | -7% | +38% | -7% | n/a | n/a | n/a |
| JEOL 6951.T | Japan | $1.98B | -3% | -18% | 11% | 14.2× | 21.3% | +10.2% |
| Shandong Weigao Group Medical Polymer 1066.HK | Hong Kong | $1.96B | -4% | +7% | 14% | 8.8× | -11.8% | +2.1% |
| Mehow Innovative 301363.SZ | China | $1.95B | -14% | +10% | 21% | 38.8× | 18.9% | +12.9% |
| Veracyte VCYT | United States | $1.94B | -40% | +17% | 17% | 14.9× | 15.1% | +34.5% |
| Celcuity CELC | United States | $3.27B | -49% | n/a | n/a | n/a | n/a | n/a |